AUS
NZ
UK
CA
USA
IND
Highlights
Clarity Pharmaceuticals shares rise sharply after a key clinical trial update
64Cu-SARTATE shows enhanced detection of NET lesions over current standard
Plans underway to progress into a registrational study with FDA guidance
Clarity Pharmaceuticals Ltd (ASX:CU6), a company listed on the ASX 200 index, is drawing attention within the healthcare and biotechnology sector following a significant development. The company released data from a clinical trial that evaluated the effectiveness of its radiopharmaceutical candidate, 64Cu-SARTATE, in detecting neuroendocrine tumours (NETs). This update has led to a sharp movement in the stock during morning trade, with CU6 outperforming the broader ASX 200 index.
Strong Diagnostic Outcomes Reported from DISCO Trial
The Phase II DISCO trial, formally registered under NCT04438304, assessed the diagnostic performance of Clarity’s 64Cu-SARTATE against the established 68Ga-DOTATATE standard. Imaging was conducted both on the same day and the day following administration, allowing comparisons between short- and long-duration detection periods.
Based on the data disclosed, 64Cu-SARTATE achieved higher lesion detection outcomes compared to 68Ga-DOTATATE. It identified a greater number of lesions across multiple readers within the study cohort. A significant portion of these lesions were classified as discordant, meaning they appeared only on one of the two scans, with the majority being visible exclusively on 64Cu-SARTATE PET/CT images.
Elevated Lesion-Level Sensitivity and Clarity of Imaging
The data showed that when histopathological correlation was available, lesion-level sensitivity for 64Cu-SARTATE was substantially elevated over that of the comparator. Lesions detected through this approach displayed high tracer uptake and low background signal, which improved reader confidence and clarity of interpretation on PET imaging.
The favourable pharmacokinetics of the radiopharmaceutical facilitated clear diagnostic imaging up to a full day post-injection. This extends the scan scheduling flexibility for clinics and imaging centres, compared to more time-sensitive radiopharmaceuticals.
Company’s Next Steps Toward Registrational Study
Clarity Pharmaceuticals stated that based on the preliminary data from the DISCO trial, preparations have begun to advance the diagnostic product into a registrational Phase III study. The next phase will be designed in consultation with the US Food and Drug Administration.
According to Clarity, the diagnostic market for NETs in the United States involves a number of scans annually and is expected to grow in the coming years. The trial results and favourable diagnostic attributes of 64Cu-SARTATE could position CU6 to further develop its footprint within this therapeutic area.
Executive Remarks and Outlook for Clarity’s Diagnostic Program
The company’s executive leadership indicated strong enthusiasm over the data and highlighted both the safety and efficacy of 64Cu-SARTATE in clinical imaging applications. The diagnostic agent demonstrated a significant advantage in lesion visualisation and detection, with liver clearance further enhancing image contrast.
As Clarity Pharmaceuticals progresses toward additional regulatory and clinical milestones, CU6 remains one of the key healthcare constituents within the ASX 200. The broader index itself saw modest movement during the same trading session, with CU6’s activity standing out against other healthcare stocks.
